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Lower omega-3 fatty acids are associated with
the presence of anti-cyclic citrullinated
peptide autoantibodies in a population at risk
for future rheumatoid arthritis: a nested
case-control study
Ryan W. Gan1, Kendra A. Young1, Gary O. Zerbe2, M. Kristen Demoruelle3,
Michael H. Weisman4, Jane H. Buckner5, Peter K. Gregersen6, Ted R. Mikuls7,
James R. O’Dell7, Richard M. Keating8, Michael J. Clare-Salzler9,
Kevin D. Deane3, V. Michael Holers3 and Jill M. Norris1
Abstract
Objective. The aim of this study was to investigate omega-3 fatty acid (FA) supplement use and omega-3
FAs in erythrocyte membranes [omega-3 FA % in erythrocyte membranes (RBC)] and their association
with anti-CCP autoantibodies in a population without RA, but who are at genetic risk for RA.
Methods. The multicentre Studies of the Etiology of RA (SERA) cohort includes RA-free subjects who are
first-degree relatives of RA probands or are enriched with the HLA-DR4 allele. In a nested case-control
study, 30 SERA cases were identified who were anti-CCP2 antibody positive. We further identified 47
autoantibody negative controls, frequency matched to cases on age at study visit, sex, race and study
site. Anti-CCP2 status, self-reported omega-3 FA supplement use and omega-3 FA % in RBCs were
obtained from a single visit.
Results. Anti-CCP2 positive cases were less likely than controls to report omega-3 FA supplement use
(odds ratio: 0.14; 95% CI 0.03, 0.68). In addition, the likelihood of anti-CCP2 positivity was inversely
associated with total omega-3 FA % in RBCs (odds ratio: 0.47; 95% CI 0.24, 0.92, for a S.D. increase).
Conclusion. The inverse association between anti-CCP2 positivity and self-reported omega-3 FA supple-
ment use and omega-3 FA % in RBCs suggests that omega-3 FAs may protect against the development
of RA-related autoimmunity in pre-clinical RA.
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Rheumatology key messages
. Omega-3 fatty acid supplement use is inversely associated with presence of anti-CCP2.
. Increasing levels of docosahexaenoic acid in erythrocyte membranes are inversely associated with the presence
of anti-CCP2.
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Introduction
Emerging evidence supports a pre-clinical period of ele-
vated RA-related autoantibodies, in the absence of clinic-
ally apparent arthritis, which precedes the development of
RA [1, 2]. In particular, autoantibodies to CCP antigen
second generation (anti-CCP2) are highly specific
(>95%) for established RA [3], and appear 35 years
prior to the onset of RA [1, 2]. Furthermore, anti-CCP2 is
strongly associated with a future diagnosis of classifiable
RA [48]. This pre-clinical phase of RA suggests that gen-
etic and environmental factors are acting prior to the de-
velopment of classifiable RA to drive the initial
development of autoantibodies. Understanding factors
that underlie the development of autoimmunity in preclin-
ical RA could ultimately lead to preventive interventions.
Heritable factors are estimated to contribute to 50% of
RA risk [9, 10], suggesting environmental factors likely ac-
count for a significant portion of the remaining risk. A
number of environmental factors have been investigated
and been found to have varying associations with RA [11].
Omega-3 fatty acids (omega-3 FA) are an environmental
factor of interest because of their anti-inflammatory proper-
ties [12]. The omega-3 FAs eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) are of particular interest,
as they serve as substrates for lipid mediators actively
involved in the resolution of inflammation [13].
Additionally, there is evidence that omega-3 FAs reduced
the risk of the development of pre-clinical islet autoimmun-
ity in children at risk for type 1 diabetes [14, 15], suggesting
a relationship between omega-3 FAs and autoimmunity.
Humans cannot endogenously synthesize the essential
omega-3 FA a-linolenic acid (ALA), or the essential
omega-6 FA linoleic acid, necessitating dietary intake
[16]. The omega-6 FA linoleic acid can be converted into
sequentially longer-chain FAs g-linoleic acid and arachi-
donic acid, while the omega-3 FA ALA can be converted
into sequentially longer-chain FAs EPA, docosapentae-
noic acid (DPA), and finally DHA [17]. Both omega-3 and
omega-6 FA conversions compete for the same rate-limit-
ing delta-6 desaturation enzyme [17]. Given that the con-
version of longer-chain FAs from the essential FAs is
inefficient at best, dietary sources of longer-chain FAs
are very important [17]. The most common type of
omega-3 FAs in American diets is ALA, with the longer-
chain omega-3 FAs EPA and DHA being less common
[18]. Dietary sources of ALA include leafy green vege-
tables and the oils of certain plants and nuts, such as
flaxseed oil. Dietary sources of EPA and DHA, and to a
lesser extent DPA, include fatty fish (e.g. salmon and
mackerel) and omega-3 FA supplements.
Epidemiological studies investigating omega-3 FAs
(measured by fish consumption) in the aetiology of RA
have found varying results, from no observed association
[1921], to non-significant trends towards an inverse as-
sociation [22, 23], to a significant inverse association [24,
25]. Additionally, a recent study found that patients with
RA had lower ALA and EPA levels in erythrocyte mem-
branes when compared with controls [26]. Evolving evi-
dence suggests that omega-3 FAs may be important in
the aetiology of RA. However, the relationship between
omega-3 FAs and the earlier phases of disease develop-
ment, including the presence of otherwise asymptomatic
pre-clinical RA-related autoimmunity, remains unknown.
This study evaluated omega-3 FA supplement use and
omega-3 FAs in erythrocyte membranes (RBCs) in relation
to anti-CCP2 positivity in participants without RA, but at
increased genetic risk of developing clinically apparent
RA. We hypothesized that omega-3 FAs would be in-
versely associated with anti-CCP2 positivity in RA-free
participants.
Methods
Study subjects
Subjects were included from the Studies of the Etiology of
Rheumatoid Arthritis (SERA), a multicentre, prospective
cohort following RA-free subjects at risk of future RA
located in the USA. The SERA at-risk population consists
of 1763 first-degree relatives (FDRs) of probands with RA
classified by the 1987 ACR criteria [27], and 634 parents
of children who participated in the Diabetes Autoimmunity
Study in the Young (DAISY). FDRs were recruited from
study sites located in Denver, Los Angeles, Seattle,
Nebraska, Chicago and New York City. Children in
Denver were recruited into DAISY based on possession
of type 1 diabetes risk alleles, which include HLA-DR4;
therefore, the parent population of DAISY children have
a higher proportion of the RA risk allele HLA-DR4 [28, 29],
making them an at-risk population. This SERA at-risk
population had no evidence of RA as determined by a
68-joint examination performed by SERA study trained
personnel at their initial study visit. This study was an ana-
lysis of the existing SERA cohort; study participants from
this nested casecontrol study and the entire SERA cohort
study provided informed, written consent. The SERA
study protocol was approved by the following institutional
review boards (IRBs) at each SERA site: Colorado Multiple
IRB, University of Nebraska Medical Center IRB,
Benaroya Research Institute at Virginia Mason IRB,
Cedars-Sinai Medical Center’s IRB, North Shore-LIJ IRB
and the Chicago Biomedicine IRB. The SERA study eth-
ical approval covers all analyses done using SERA data.
RA-related autoantibodies were measured in SERA par-
ticipants as previously described [30]. RF was measured
by nephelometry (Dade Behring, Newark, DE, USA) and
RF isotypes, (IgG, IgM and IgA) were measured by ELISA
(Quanta Lite) kits and reported in IU/ml, following manu-
facturer recommendations (Inova Diagnostics, San Diego,
CA, USA). Cut-offs for positivity for RF in serum (for both
nephelometry and isotype ELISAs) were defined using a
threshold that was higher than that observed in >95% of
490 randomly selected healthy blood donor controls from
the Denver area. Anti-CCP2 was measured in serum using
ELISA kits (Diastat; Axis-Shield, Dundee, UK). Positivity
for anti-CCP2 was defined as 55 units, based on manu-
facturer specifications.
SERA participants were genotyped for HLA shared epi-
tope at the Benaroya Research Institute at Virginia Mason
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in Seattle, as described previously [30]. DNA was
screened for HLA-DR4 and HLA-DR1 positivity using spe-
cific PCR primers. The HLA-DR4 subtypes considered as
shared epitope positive included DRB1*0401, *0404,
*0405, *0408, *0409, *0410, *0413, *0416, *0419 and
*0421. The HLA-DR1 subtypes considered as shared epi-
tope positive included DR1*0101, *0102, *0104, *0105,
*0107, *0108 and *0111. For this study, a participant is
deemed shared epitope positive if they are either DR4 or
DR1 subtype positive.
Nested casecontrol study
A nested casecontrol study design in the SERA at-risk
cohort was utilized, as outlined in Fig. 1. Cases were
defined as those testing anti-CCP2 positive on at least
one visit, and never testing anti-CCP2 negative at subse-
quent visits (for participants with multiple visits), with
stored RBCs available (n = 30). There were 18 anti-
CCP2-positive participants who were not selected as
cases because either they did not have stored RBCs
available, or they lost anti-CCP2 positivity on subsequent
visits. These 18 were generally similar to the 30 anti-
CCP2-positive cases selected for this study with regard
to mean age at visit (44 vs 46 years), sex (83% vs 70%
female) and race (67% vs 60% non-Hispanic Whites).
Controls were selected by identifying 1887 at-risk partici-
pants who were autoantibody negative for RF (all assays)
and anti-CCP2 on all visits, of which 47 controls were
identified that were always negative for anti-CCP2 and
RF on all visits with stored RBCs. These 47 controls
were frequency matched to cases so that the distributions
of age at study visit, sex, race and site were not statistic-
ally different between the two groups, thereby controlling
for these potential confounders and increasing efficiency
via study design [3133]. The selected cases and controls
came from five SERA sites: Denver (n = 32), Los Angeles
(n = 26), Nebraska (n = 9), Chicago (n = 9) and New York
(n = 2). There was no familial relationship among and be-
tween anti-CCP2 cases and controls.
Omega-3 FA exposure measurement
Participant self-reported supplement use within the past
year up until the date of the study visit was obtained by a
standardized SERA questionnaire at the time of study
visit. Supplement use variables are binary (yes or no)
and are derived from the dietary supplement use question
on the SERA epidemiological questionnaire that was rou-
tinely collected at each study visit. Participants were
asked to report use of any supplement within the past
year. If a participant reports yes to use of any supplement,
they were then asked specific questions about use of fish
oil, fish liver oil or omega-3 FA or use of multivitamins that
contained omega-3 FAs in the past year. Additionally, an-
other supplement variable was created that indicated use
of any supplement (i.e. vitamin D, antioxidants, etc.)
except omega-3 FA supplements. SERA did not collect
information on dietary intake.
FIG. 1 Flow diagram of the casecontrol study design nested within the SERA at-risk cohort
SERA: multicentre Studies of the Etiology of RA.
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Percentages of omega-3 FAs in erythrocyte membranes
(omega-3 FA % in RBCs) were measured in cases and
controls as a biomarker of fatty acid status/exposure, as
RBCs exhibit an in vivo lifespan of 120 days and allow
one to capture the longer-term status of omega-3 FAs in
the body, which corresponds to both dietary intake and
physiological processes (i.e. conversion to longer-chain
FAs) [34]. RBCs were separated within 30 min of blood
draw, flash frozen in liquid nitrogen and stored at 70C.
In cases, the RBC sample collected at the first anti-CCP2-
positive visit was assayed. In controls, the RBC sample
collected from the frequency-matched age at visit sample
was assayed. Selected samples were then sent to the
University of Florida Analytical Toxicology Core
Laboratory, where lipids were extracted for measurement
of the FAs present. Samples were methylated and
analysed by gas chromatography (Hewlett-Packard
6890; Agilent, Santa Clara, CA, USA) with mass spectral
detection (Hewlett-Packard 5973; Agilent, Santa Clara,
CA, USA), using an internal standard to monitor perform-
ance. Triplicate analysis of a composite control RBC
sample yielded coefficients of variation <15% for all ana-
lytes. Fatty acids were measured as a percentage of the
total lipid weight in the RBC sample [(mg FA/mg total
lipid)*100]. The omega-3 FAs analysed included: 18:3
omega-3 (ALA), 20:5 omega-3 (EPA), 22:5 omega-3
(DPA) and 22:6 omega-3 (DHA), and a summed total of
the aforementioned omega-3 FAs (total omega-3 FA % in
RBCs). In addition, we created an omega-3 FA % in RBCs
variable that summed EPA and DHA, which are the two
most common types of omega-3 FA found in omega-3 FA
supplements and fatty fish.
Statistical methods
The association between self-reported supplement use
and anti-CCP2 casecontrol status was analysed using
logistic regression analyses, adjusting for age at visit,
sex, race, study site, current smoking status, presence
of the shared epitope, reported education and reported
income. Statistical adjustments of the frequency-matched
variables were made as an analytical approach to capture
any residual imbalance between cases and controls [31,
33]. Smoking and shared epitope were adjusted for to
allow for their well-known associations with RA [35].
Adjustments for education and income were made on
the basis of their potential confounding effects between
omega-3 FAs and anti-CCP2.
The relationship between omega-3 FA supplement use
and omega-3 FA % in RBCs, regardless of autoantibody
status, was assessed using a t-test, allowing for unequal
variances. If there was a significant mean difference in
total omega-3 FA % in RBCs by omega-3 FA supplement
use status, subsequent t-tests were performed evaluating
the specific omega-3 FAs (ALA, EPA, DPA, DHA) by
omega-3 FA supplement use status.
The relationship between omega-3 FA % in RBCs and
anti-CCP2 casecontrol status was assessed using a t-test,
allowing for unequal variances. If there was a significant
mean difference in total omega-3 FA % in RBCs by anti-
CCP2 casecontrol status, subsequent t-tests were per-
formed evaluating the specific omega-3 FAs (ALA, EPA,
DPA, DHA), comparing anti-CCP2 cases with controls.
Plots were created to demonstrate the mean omega-3
FA % in RBCs for ALA, EPA, DPA and DHA by omega-3
FA supplement use status, and then by anti-CCP2
casecontrol status. Similar plots were created for
omega-6 FA % in RBCs (total omega-6 FA, LA, g-linoleic
acid and arachidonic acid) and included as supplementary
Fig. S1, available at Rheumatology Online for comparison.
The distribution of omega-3 FA % in RBCs was as-
sessed for normality. Due to skewness, both log-trans-
formations and non-parametric tests were considered,
but yielded essentially the same results as the t-tests.
Logistic regression was used to evaluate increasing
levels of omega-3 FA % in RBCs and anti-CCP2 positivity,
adjusting for age at visit, sex, race, site, current smoking
status, shared epitope, education and income.
Subsequent analyses were performed on ALA, EPA,
DPA, DHA and EPA + DHA if a significant association be-
tween total omega-3 FA % in RBCs and anti-CCP2 posi-
tivity was observed. All omega-3 FA % in RBCs values
were standardized (i.e. to calculate the odds ratio for a 1
S.D. increase in FA) to allow comparisons across FAs.
Statistical adjustments were made based on the same
rationale as outlined above.
All statistical analyses were performed using SAS soft-
ware, Version 9.3 of the SAS System for Windows
(Copyright, SAS Institute Inc. SAS, and all other SAS
Institute Inc. product or service names are registered
trademarks or trademarks of SAS Institute Inc., Cary,
NC, USA). All plots were created using the ggplot2 pack-
age for R software, version 3.0.2 [36].
Results
Descriptive characteristics of the cases and controls are
presented in Table 1. Anti-CCP2 cases were less likely to
report using omega-3 FA supplements when compared
with controls (odds ratio: 0.14, 95% CI 0.03, 0.69,
P = 0.02), adjusting for age at visit, sex, race, current
smoking status, shared epitope, study site, education
and income (Table 2), which was not observed with use
of other supplements in general (Table 2). Among the
omega-3 FA supplement users, on average anti-CCP2
cases reported using omega-3 FA supplements for 4.5
months over the past year, compared with 10.25 months
in controls.
Participants who reported use of omega-3 FA supple-
ments in the past year had significantly higher total
omega-3 FA % in RBCs, compared with those who did
not report use of omega-3 FA supplements (7.91% vs
6.24%, P< 0.01). Subsequent analyses of specific
omega-3 FA % in RBCs found similar significant results
for the longer-chain FAs EPA and DHA (Fig. 2). These re-
sults suggest that the questionnaire accurately repre-
sented whether participants were indeed using
supplements containing omega-3 FAs.
On average, total omega-3 FA % in RBCs values were
significantly lower in anti-CCP2 cases compared with
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controls (6.09% vs 6.97% P = 0.02). Subsequent analyses
of specific omega-3 FA % in RBCs found similar, but mar-
ginally significant results for the longer-chain FA EPA, and
significant results for DHA (Fig. 3). While the focus of our
analysis was to examine omega-3 FA % in RBCs as a bio-
marker of omega-3 FA supplement use, as a comparison
we also present omega-6 FA % in RBCs in these subjects
(supplementary Fig. S1, available at Rheumatology Online).
Levels of omega-6 FA % in RBCs were not statistically
different between anti-CCP2 cases and controls.
Adjusting for age at visit, sex, race, site, current smoker,
shared epitope, education and income, anti-CCP2 cases
were significantly more likely to have lower total omega-3
FA % in RBCs (by 1 S.D.) than controls (Table 3). Subsequent
analyses of individual omega-3 FAs found that anti-CCP2
cases were significantly more likely to have lower levels of
DHA and EPA + DHA, specifically, than controls.
Discussion
Our results suggest an inverse association between omega-
3 FAs and the RA-specific autoantibody anti-CCP2 in par-
ticipants who are without RA but at an increased risk of
future disease. These findings support those from other
studies demonstrating that omega-3 FAs are inversely
associated with RA [2426]. Perhaps most intriguing is the
demonstrated inverse association of omega-3 FAs and anti-
CCP2 positivity in arthritis-free participants who are being
followed prospectively through the unique SERA study,
suggesting that omega-3 FAs may affect RA pathogenesis
during the pre-clinical phase of disease.
Strengthening the validity of our findings are the
observed associations between both self-reported
omega-3 FA supplements, and a biomarker measurement
of omega-3 FA % in RBCs with anti-CCP2 positivity.
Furthermore, we did not observe associations between
biomarkers of omega-6 FA % in RBCs and anti-CCP2
positivity, supporting our conclusions that these associ-
ations are specific to omega-3 FAs. Our variable assess-
ing self-reported omega-3 FA supplement use within the
past year is unlikely to be subject to differential recall be-
tween our cases and controls, as both groups were un-
aware of their anti-CCP2 status at the time they self-
reported their FA supplement use. Furthermore, the
omega-3 FA % in RBCs biomarker quantified a time
period of 120 days prior to measurement. When con-
sidering both omega-3 FA supplement use and omega-3
FA % in RBCs in tandem, they provide convincing and
supportive evidence that omega-3 FAs are inversely asso-
ciated with anti-CCP2 positivity in arthritis-free partici-
pants who are at-risk of future RA.
Notably, we observed a strong, significant inverse as-
sociation between omega-3 FA supplement use and anti-
CCP2 positivity that was not observed with the use of
other dietary supplements. This observation could sug-
gest that the apparent protective effect is due to
omega-3 FAs and not due to other beneficial factors asso-
ciated with supplement use (i.e. a healthier lifestyle in gen-
eral). It is also worth noting that we did not collect
information on dietary sources of omega-3 FAs (i.e. fatty
fish consumption). However, since intake of fatty fish in
the USA is relatively low [37], and taking DHA and DHA/
EPA supplements accounts for increases ranging from
44% to >100% in RBC FA content [38, 39], a large
amount of the variability in FA status is due to supplement
use. Moreover, participants who take fish oil supplements
TABLE 1 Study population characteristics comparing anti-CCP2-positive cases with anti-CCP2-negative and
RF-negative controls
Descriptive variable Anti-CCP2 (+) (n = 30) Control (Ab) (n = 47) P-value
Age at study visit, mean (S.D.), years 45.6 ± 16.5 48.6 ± 14.4 0.39
Race, non-Hispanic Whites, n (%) 18 (60.0) 30 (63.8) 0.74
Gender, female, n (%) 21 (70.0) 35 (74.5) 0.67
Education,>High School, n (%) 20 (66.7) 37 (78.7) 0.24
Income, 5$40 000 annually, n (%) 21 (70.0) 33 (70.2) 0.98
Study site, Denver, Colorado, n (%) 12 (40.0) 20 (42.6) 0.82
Shared epitope, positive, n (%) 22 (73.3) 31 (66.0) 0.50
Ever smoker, yes, n (%) 8 (26.7) 21 (44.7) 0.11
Current smoker, yes, n (%) 2 (6.7) 2 (4.6) 0.64
TABLE 2 Association between self-reported supplement use (yes vs no) and anti-CCP2 positivity
Self-reported supplement Anti-CCP2 (+) (n = 30) Control (Ab) (n = 47) Odds ratioa (95% CI) P-value
Other supplements, yes, n (%)b 16 (53.3) 21 (44.7) 1.68 (0.60, 4.72) 0.33
Omega-3 FA supplement, yes, n (%) 2 (6.7) 16 (34.4) 0.11 (0.02, 0.61) 0.01
aAdjusted for age at visit, sex, race, site, current smoker, shared epitope, education and income. bIncludes all other dietary
supplements except omega-3 FA supplements. FA: fatty acid.
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are more likely to consume more fish than those who do
not take these supplements [40], where perhaps we may
be underestimating the difference in FA status between
our cases and controls. Therefore, accounting for dietary
sources of EPA and DHA would likely not change the in-
verse association observed between omega-3 FA supple-
ment use and anti-CCP2 positivity.
We took steps to guard against false discovery through
the use of a priori hypotheses and a statistical approach
that limits unwarranted comparisons. Based on our stat-
istical approach, as well as the supporting evidence from
two omega-3 FA measures (supplement use and omega-3
FA % in RBCs), we believe that our observed associations
are not due to chance discoveries as a result of multiple
comparisons, and warrant further investigation [41].
We adjusted for current smoking status rather than
ever-smoking status in our models based on the hypoth-
esis that current smoking would be a more relevant meas-
ure for the presence of anti-CCP2 in a RA-free population.
Interestingly, no association was observed between
smoking and anti-CCP2 positivity in our study. While
smoking is a well-known risk factor for ACPA-positive
RA, studies suggest that smoking may not be associated
with ACPA positivity in individuals without RA [4245]. We
also note that we did not observe an association between
shared epitope positivity and anti-CCP2 positivity, a result
that is supported by other studies [4246]. In aggregate,
these findings suggest that smoking and shared epitope
positivity may not act to initially trigger anti-CCP positivity,
but will need to be explored carefully in future studies.
Anti-CCP2 was prevalent in2% of the SERA at-risk RA-
free cohort, which is not surprising, given that while the risk
of development of RA in FDRs is increased over that of the
general population [47], RA is relatively uncommon in the
general population (prevalence of 0.51%) [48]. It is worth
noting that this study consists of a relatively small sample of
30 anti-CCP2 cases and 47 controls. While our study had
adequate power to detect the aforementioned novel asso-
ciations between two different markers of omega-3 FA ex-
posure and anti-CCP2 positivity, it is possible that due to
limited power, associations of smaller magnitude may exist
but were not detected. This is the first study to observe
these associations in an at-risk population without RA. In
order to dismiss the possibility of type 1 error and lend
FIG. 2 Mean and 95% CIs of omega-3 FA % in RBCs for ALA, EPA, DPA and DHA by omega-3 FA supplement use status
(Yes, n = 18; No, n = 59)
Dots represent individual participant omega-3 FA % in RBCs. A P< 0.05 indicates a significant difference in means
between the two groups. RBC: erythrocyte membranes; ALA: omega-3 FA a-linolenic acid; EPA: omega-3 FAs eicosa-
pentaenoic acid; DPA: docosapentaenoic acid; DHA: docosahexaenoic acid; FA: fatty acid.
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further evidence to this finding, it is important that this
question be studied in other populations.
Furthermore, we were not able to assess other markers
of inflammation, including cytokines (as we did not collect
these data), nor the relationship between CRP, omega-3
FAs and anti-CCP2, as the sample size prohibited in-
depth analysis of this relationship. In addition, we were
unable to evaluate the relationship between omega-3 FAs
and RF, as due to the casecontrol study design and our
case definition, we had no RF-positive, anti-CCP2-negative
individuals in this study. However, given our intriguing
finding that omega-3 FAs appear to be protective against
the presence of anti-CCP2, further exploration is needed to
determine whether omega-3 FAs are associated with RF
and other inflammatory markers, which could elucidate
whether omega-3 FAs play a larger role in the pathogenesis
of RA.
In terms of potential mechanisms explaining our find-
ings, omega-3 FAs, and in particular DHA and EPA, are
known to have important anti-inflammatory and inflamma-
tion-resolving properties [13]. In particular, DHA and EPA
FIG. 3 Mean and 95% CIs of omega-3 FA % in RBCs for ALA, EPA, DPA and DHA by anti-CCP2 status [anti-CCP2(+)
n = 30, Control Ab() n = 47]
Dots represent individual participant omega-3 FA % in RBCs. P< 0.05 indicates a significant difference in means be-
tween the two groups. RBC: erythrocyte membranes; ALA: omega-3 FA a-linolenic acid; EPA: omega-3 FAs eicosa-
pentaenoic acid; DPA: docosapentaenoic acid; DHA: docosahexaenoic acid; FA: fatty acid.
TABLE 3 Adjusted association between anti-CCP2 posi-
tivity and levels of erythrocyte membrane (RBC) omega-3
FAs, in anti-CCP2 cases (n = 30) vs controls (n = 47)
Omega-3 FA %
in RBCs
Adjusted odds
ratioa
(95% CI) P-value
Total omega-3 FA 0.44 (0.21, 0.92) 0.03
ALA (18:3 omega-3) 0.87 (0.52, 1.45) 0.59
EPA (20:5 omega-3) 0.55 (0.25, 1.21) 0.14
DPA (22:5 omega-3) 0.65 (0.38, 1.13) 0.13
DHA (22:6 omega-3) 0.50 (0.26, 0.97) 0.04
EPA + DHA 0.47 (0.23, 0.97) 0.03
aAdjusted for age at visit, sex, race, site, current smoker,
shared epitope, education and income. The odds ratios re-
ported are for a S.D. difference in omega-3 FA %. S.D. are
1.70 for total omega-3 FA, 0.06 for ALA, 0.58 for EPA, 2.26
for DPA, 3.54 for DHA and 4.12 for EPA + DHA. ALA: omega-
3 FA a-linolenic acid; EPA: omega-3 FAs eicosapentaenoic
acid; DPA: docosapentaenoic acid; DHA: docosahexaenoic
acid; FA: fatty acid.
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may suppress certain cytokines, such as IL-6, that partici-
pate in inflammatory responses that could ultimately result
in activation and maturation of autoreactive B cells [49, 50].
In addition, there are also recently characterized omega-3
FArelated pro-resolution pathways, such as the generation
of the EPA- and DHA-derived lipoxin, resolvin and protectin
compounds [13], which could also, in part, explain these
findings. These compounds are thought to actively play a
role in the resolution of inflammation (e.g. inhibiting recruit-
ment of neutrophils), and serve as bridges between the
innate and adaptive immune systems (e.g. suppression of
cytokines) [13]. These potential mechanisms warrant further
evaluation in experimental and clinical studies that are
better able to explore the specific role of omega-3 FAs in
the generation of, as well as the persistence and evolution
of, RA-related autoimmunity.
In summary, the results presented in this study could
offer insight into a potential mechanism of action that
would explain other observed relationships in which
omega-3 FAs are protective against RA, perhaps through
the early inhibition of RA-related autoimmunity. Future re-
search should involve replication of our findings, and fur-
ther exploration into the mechanisms that underlie the
relationship between omega-3 FAs and RA in an at-risk
population.
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